Hello. Sir, one is, if you can explain importance of Eugia Unit-5 versus Unit-3, I mean, Unit-3 has been discussed a lot, but if you can give some more clarity with regards to how Unit-5 versus Unit-3.
This is helpful. And Unit-3 would be also having eight lines or would it be…?
Yeah, thanks for the opportunity. My first question is now with this Unit 3 classification also kind of getting out of the way things getting resolved, is the board probably planning to go back to the proposed spin-off or IPO listing for Eugia?
Great, sir. So, one question is on the margin. You mentioned about Rs. 100 crores one off this quarter, which gradually will reduce with the operating scale and the business ramp up. But as the business scales up, it will take a while, I mean, it will take its time to come to the company level margin. So, overall, we maintain at 21 %-22%, while in absolute terms, the margin is definitely ramp up.
Yes, thanks for the opportunity. Sir, with the Revlimid revenues back in H2, do we expect to meet the old run rate US$ 600 million overall for injectables?
Okay, got it. And any overall guidance for the second half for sales EBITDA?
Hello, hi. Thank you for the opportunity. My first question is for the products approvals, we have received from the injectable side, how many would be from Eugia 3?
Got it. Second question, your perspective around the generic prices in the U.S. market, particularly around the current times?